Semaglutide
The most rigorously trialled compound in the peptide space. Multiple large phase 3 randomized trials with cardiovascular outcome data.
Metabolic & Weight
Semaglutide (oral)
The same peptide as injectable semaglutide, formulated with an absorption enhancer so it survives the stomach. Approved for type 2 diabetes, with a completed cardiovascular outcomes trial.
Overview
Semaglutide is a peptide, and peptides are normally destroyed by stomach acid and enzymes. This formulation co-packages it with SNAC, a compound that locally raises the pH right at the stomach wall and helps the peptide cross into the bloodstream before it is broken down. Once absorbed it behaves exactly like injected semaglutide. The trade-off is that absorption is low and erratic, which is why it must be taken fasted, with a sip of water, and nothing else for half an hour.
Semaglutide co-formulated with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). SNAC buffers gastric pH locally and promotes transcellular absorption across the gastric epithelium, protecting the peptide from pepsin. Absolute bioavailability is roughly 0.4–1%, with high inter- and intra-individual variability, hence the strict fasting administration requirement. Once systemic, pharmacology is identical to subcutaneous semaglutide: GLP-1R agonism with an albumin-binding C18 diacid side chain giving a ~1-week half-life. PIONEER phase 3 programme and the PIONEER 6 and SOUL cardiovascular outcomes trials support the approval.
Research areas
Type 2 diabetesObesityCardiovascular risk
Dosing reported in the literature
Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.
| Protocol as reported | Source |
|---|---|
| 3 mg once daily for 30 days, then 7 mg once daily, increasing to 14 mg if neededTake on an empty stomach with up to 120 ml of water, then wait at least 30 minutes before eating, drinking or taking other oral medicines. | Approved product labelling |
| 50 mg once daily in the OASIS weight management programme | OASIS 1, The Lancet 2023 |
Trial status
PIONEER phase 3 programme completed, plus PIONEER 6 and the SOUL cardiovascular outcomes trial.
Reported safety signals
- Absorption is highly sensitive to food and fluid — taking it incorrectly can reduce exposure to near zero.
- Nausea, vomiting and diarrhoea are common, particularly during dose escalation.
- Boxed warning for thyroid C-cell tumours; contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2.
- Diabetic retinopathy complications were seen in some semaglutide trials in patients with pre-existing retinopathy and rapid glucose lowering.
Common questions
Is oral semaglutide as effective as the injection?
At the doses approved for diabetes, glycaemic effect is comparable. For weight management, the 50 mg oral dose in OASIS 1 produced weight loss similar to injectable semaglutide 2.4 mg. The practical difference is the administration discipline the tablet demands.
Primary sources
- 01
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
- 02
Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes (PIONEER 6)
- 03
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
Medical disclaimer
This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.
How this profile was built →